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Abstract
Objective
Concern for side-effects of therapy related to treatment of childhood malignancies 
is becoming an increasingly important topic. In this study, we evaluated extent 
of vincristine (VCR) induced neurotoxicity in a group of children who underwent 
chemotherapy, with VCR being part of the regimen. 
Materials & Methods
In this investigation, for 75 children (54% boys, 46% girls), aged between 1 to 14 
(mean 6.5±4.3) years, serial weekly neurological examinations were performed; 
of the 75, 70 had acute lymphoblastic leukemia and 5 Wilm’s tumor. All patients 
were on a chemotherapy protocol of at least 4 consecutive VCR (1.5mg/m2) 
injections. 
Results
 Decreased deep tendons reflexes were seen in the Achilles reflex in 78%, and 
the patellar reflex in 53% of patients. Muscle weakness was found in 70% of 
patients, being mild in 76% of them. Four percent of patients showed severe 
weakness. Petosis, jaw pain, hoarseness, abdominal pain and constipation were 
seen in 15%, 6%, 12%, 12% and 12% respectively. Paresthesia was observed in 
32 of 52 patients, over 4 years old. No cases of foot drop, urinary retention or 
facial nerve palsy were seen in this patient group. 
Conclusion
Children on usual doses of vincristine regimen may have neuropathic side 
effects but most of these side effects are mild and not troublesome.
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Introduction   
As a consequence of the significant improvements in the treatment of childhood 
acute lymphoblastic leukemia (ALL), monitoring of the therapy related side effects 
has become increasingly important. Vincristine (VCR) is a key drug used in ALL 
chemotherapy and neurotoxicity is its most common side effect (1-4); the extent 
and severity of its side effects that may reduce drug administration or cause its 
discontinuation and also interfere with the treatment of the malignancy are important. 
Literature available reveals discrepancies in reports between frequency and severity 
of VCR side effects (5-8). This study aimed to evaluate the extent and importance 
of neurological side effects experienced by a population of Iranian children in the 
Mofid children hospital on VCR therapy during the induction phase of treatment of 
ALL.
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Materials & Methods  
In this descriptive cross sectional study, all patients 
with pathological confirmation of ALL or Wilm’s 
tumor, who had undergone a chemotherapy protocol 
including at least four consecutive weekly VCR 
injections in the hematology–oncology ward of the 
Mofid hospital in Tehran, were enrolled; patient 
histories were studied in detail and complete 
systemic and neurological physical examinations 
were conducted for each. Patients with underlying 
neurological disease, previous history of VCR 
injections, relapsed disease or CNS leukemia were 
excluded from the study. ALL patients were divided 
into three risk groups, the standard, intermediate 
and the high risk groups. Induction of remission 
treatment included prednisolone (2 mg/kg/day 
maximum 60 mg) for 4 weeks, 4 weekly injections 
of VCR (1.5 mg /m2, maximum 2 mg) 8 injections 
of L–Asparginase (10/000 u /m2, twice a week), 
4 intratechal injections of methotraxate, ara-C, 
hydrocortisone with standard dosage for all patients 
and 4 additional injections of adriablastin (25 mg /
m2) for the high risk patients. Patients with Wilm’s 
tumor were treated according to the Wilm’s tumor 
international study IV. All patients were visited and 
physically examined weekly by a hematology fellow 
and a child neurologist and the following data were 
collected on days  0, 7, 14, 21, 28 and 56: Deep 
patellar and Achilles tendon reflexes (graded based 
on 0 to 3 scale); lower extremity muscle weakness 
(graded on the 0 to 5  conventional force measuring 
scale), jaw pain, paresthesia, constipation, abdominal 
pain, urinary retention (based on patient’s self report), 
petosis, hoarseness and facial nerve palsy (based on 
physical examination). Data were then analyzed by 
SPSS software using descriptive statistics. Numerical 
data are presented as mean ± standard deviation. We 
used the descriptive Statistics, t-test and chi square 
to analyze data; all the statistical analyses were done 
with 95% confidence interval when appropriate and 
P<0.05 was considered significant.
Results  
Between June 1996 to December 1998, 99 children 
with acute lymphoblastic leukemia and 5 with Wilm’s 
tumor were admitted to the hematology–oncology 
ward of Tehran’s Mofid hospital; 29 of them were 
excluded from the study, 5 due to discontinuation of 
treatment, 8 died during the chemotherapy induction, 
3 were moved to other centers and 9 were unwilling 
to participate in the study, leaving 75 patients, 
pathologically confirmed for ALL (n=70) and Wilm’s 
tumor (n=5). Age at diagnosis ranged from 11 months 
to 14 years (mean 6.5±2.3 y); 41(54 %) were male 
and 34(46 %) female. None of them had any focal 
neurologic deficit or malignant central nervous 
system involvement at initiation of treatment. The 
time of appearance of symptoms and signs is shown 
in Table 1. Decreased patellar and Achilles tendon 
reflexes were seen in 40(53%) and 59 (78%) of 
patients respectively; only 5% had decreased deep 
tendon reflexes in day 7, whereas 54% of patients 
showed decreased deep tendon reflexes on day 14. 
Lower extremities muscle weakness was seen in 53 
(70 %) of patients, which had mostly (45.5%) started 
from day 14 (table 2); in 76 % of these patients, 
muscle force was scored 4 (slight muscle weakness), 
whereas it was severely decreased in 2 (4%), as shown 
in Table 3. In 2 of the patients, profound muscle 
weakness, preventing them from being able to sit 
developed on day 28. In 5 patients muscle weakness 
was significantly unilateral. 
Petosis was seen in 11 (15%) patients, all less than 6 
years; in one, it was bilateral, starting on day 35 and 
continuing until day 56. In the Wilm’s tumor patients 
in whom VCR injections continued after day 21, 
petosis was seen in 4 out of 5 patients. Paresthesia, as a 
subjective symptom, was not reliable in patients under 
the age of 5 years, but in the remaining it occurred in 
32 of the 52 patients. Other neurologic side effects 
documented were jaw pain in 5 patients, hoarseness 
in 9, abdominal pain, without any confirmed cause, 
in 9 and constipation in 9. No foot drop, urinary 
retention or facial nerve palsy were detected. One 
patient had significant orthostatic hypotension from 
day 14 till day 45 and, in 12% of patients, abdominal 
pain without any proven non-neurological origin 
but most probably due to autonomic neuropathy, 
was reported (not included in study variables). No 
significant difference in the neurotoxic side effects 
VINCRISTIN INDUCED NEUROTOXICITY
41Iran J Child Neurology  June  2009
of VCR was found between boys and girls. Neuropathic symptoms and signs were more significant in children 
older than 4 years of than in the younger ones (p value<0.05). The only side effect which was significantly more 
common in younger children was petosis. 

















VCR 1.5 mg/m2 weekly ×4 doses
Prednisolon 2mg/kg × 28 days
L-Asparginase 10/000 u/m2 × 8 doses
Adriablastin 25 mg/m2 ×4 doses (only high risk patients)
Wilms tumor Treatment international wilms tumor study IV
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Table 2 : the time of appearance of symptoms and signs of neurotoxity in study participants.
Symptom
time of appearance(day)
7 14 21 28 56 56<
total    
percentage
Decreased  Achilles 
reflex
3(5%) 32(54%) 7(12%) 10(17) 7(12%) - 59(100%)    %78
Decreased patellar 
reflex
2(5%) 18(45%) 10(25%) 7(18%) 3(%7) - 40(100)      %53
Muscle weakness _ 24(45.5%) 16(31%) 4(7.5%) 6(%10.5) 3(%5.5) 53(100%)   %70
Petosis _ 2(18%) - 2(18%) 1(9%) 6(55%) 11(100%)  15%
Hoarsness _ 2(22%) - 5(56%) 2(22%) - 9(100%)    12%
Foot drop _ _ _ _ _ _ _
Urinary retention _ _ _ _ _ _ _
Facial nerve palsy _ _ _ _ _ _ _
Constipation _ 3(33.5%) 2(22%) 3(33.5%) 1(11%) _ 9(100%)    12%
Jaw pain 5(100%) _ _ _ _ _ 5(100%)     6%
Paresthesia
[> 4 years  old (52 
patients)]
5(13%) 20(55%) 7(19%) 5(13%) _ _ 37(100%)   71%
Table 3: Severity of muscle weakness in study participants
      Muscle force          Number of patients
 0           _
 +      2(4%)
 ++      5(9%)
 +++      6(11%)
 ++++      40(76%)
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Discussion  
In our study, different neurological side effects of VCR 
were seen in patients. Decreased deep tendon reflexes 
(78%) and muscle weakness (70%) were the most 
common side effects, whereas gross motor disturbances 
seen were usually less severe. Time of onset of symptoms 
and signs was mostly on day 14 or later, the only 
symptom appearing earlier being jaw pain. The type and 
severity of sensory motor neuropathies observed in our 
patients receiving VCR are similar to those reported in 
other studies (5). Our data shows that the drug, rather 
than the underlying disease, is responsible for the 
neuropathy because all patients had normal neurological 
examination initially. In this study, the neuromyopathy 
was not too troublesome although it developed in most 
patients. These results are compatible to those reported 
by Reindors–Messelink et al who found neurotoxicity 
of VCR in usual doses is tolerable(6), indicating that 
if the drug is effective in treating the disease, its toxic 
effects may be acceptable. In the De Angelis study of 
patients treated with VCR including regimens, moderate 
to severe neuropathy and myopathy were found in all 
patients; initially VCR impaired fine motor coordination 
and corticosteroids were associated with the delayed 
development of proximal muscle weakness; the author 
concluded that weakness is predictable during intensive 
VCR/ corticosteroid therapy(7). Although the incidence 
and severity of neuropathy and myopathy were higher in 
this study than ours, but to some degree, corticosteroid 
therapy could also explain the  gross motor dysfunction 
in our patients.  Haim M et al also reported peripheral 
neuropathy signs in all patients under treatment with 
VCR, in particular muscle cramp that correlated with 
VCR cumulative dosage(8). In his study, Vainioupaa 
reported fine and gross motor dysfunctions in only 18% 
and 30% of  patients under VCR chemotherapy, with the 
neurologic side effects being more common in young 
children(9). In our study it seems than neurologic side 
effects are associated with the cumulative dosage, results 
in agreement with most previous reports; however 
Harrman reported motor performance is lower in VCR 
treated patients and is not correlated to cumulative 
dosage(10). 
Gastrointestinal neurotoxicity including abdominal 
pain and constipation, and side-effects related to 
autonomic neuropathy, were each (abdominal pain 
and constipation) seen in 12% out of our patients, with 
approximately one-third of these effects occuring on 
day 7. Fortunately our patient with gastrointestinal 
neuropathy suffered no life-threatening effects, but 
there are some reports that emphasize these type of 
side effects could even be fatal. Autonomic neuropathy 
may occur in absence of somatic neuropathy. In case of 
abdominal pain if ileus or constipation simultaneously 
persists, neuropathy as the cause of abdominal pain 
is more suspicious(11-12). We couldn't exclude the 
neurological side effects of triple intratechal therapy or 
myopathic side effects of corticosteroids in our patients. 
The same side effects in our small group of Wilm’s 
tumor patients, who received no corticosteroids or 
intrathecal chemotherapy, emphasize that neurotoxicity 
is mostly due to VCR; however because of the limited 
number of Wilm’s tumor cases, it was not statistically 
proven. Although triple interatechal therapy mostly 
results in central nervous system side effects and 
corticosteroids usually cause proximal myopathy rather 
than neuropathy, sometimes clear differentiation is not 
easy.
In conclusion, the neuropathic side effects of VCR are 
common but are not usually troublesome and can be 
tolerated. 
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